Human CLTA Protein

<strong>Human CLTA Protein</strong>_x000D_ <strong>Catalog number:</strong> B2011979_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 26.2 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20 °C_x000D_ <strong>Keywords:</strong> LCA protein_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and toxicity Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):356-365._x000D_ 2: Anderson RH, Kerkvliet JG, Otta JJ, Ross AD, Leiferman PC, Hoppe AD, Francis KR. Generation of a CLTA reporter human induced pluripotent stem cell line, CRMi001-A-1, using the CRISPR/Cas9 system to monitor endogenous clathrin trafficking Stem Cell Res. 2018 Dec;33:95-99._x000D_ 3: Yang F, Chen Y, Xue Z, Lv Y, Shen L, Li K, Zheng P, Pan P, Feng T, Jin L, Yao Y. High-Throughput Sequencing and Exploration of the lncRNA-circRNA-miRNA-mRNA Network in Type 2 Diabetes Mellitus Biomed Res Int. 2020 May 20;2020:8162524._x000D_ 4: Abramiuk M, Bębnowska D, Hrynkiewicz R, Polak PNG, Kotarski J, Roliński J, Grywalska E. CLTA-4 Expression is Associated with the Maintenance of Chronic Inflammation in Endometriosis and Infertility Cells. 2021 Feb 25;10(3):487._x000D_ 5: Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, Mutti L. Anti-CTLA-4 therapy for malignant mesothelioma Immunotherapy. 2017 Mar;9(3):273-280._x000D_ 6: Ponnambalam S, Jackson AP, LeBeau MM, Pravtcheva D, Ruddle FH, Alibert C, Parham P. Chromosomal location and some structural features of human clathrin light-chain genes (CLTA and CLTB) Genomics. 1994 Dec;24(3):440-4._x000D_ 7: Reschke R, Ziemer M. Rechallenge with checkpoint inhibitors in metastatic melanoma J Dtsch Dermatol Ges. 2020 May;18(5):429-436._x000D_ 8: Perez-Santos M. Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors Pharm Pat Anal. 2020 Sep;9(5):149-154._x000D_ 9: Xi Z, Jones PS, Mikamoto M, Jiang X, Faje AT, Nie C, Labelle KE, Zhou Y, Miller KK, Soberman RJ, Zhang X. The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas Front Endocrinol (Lausanne). 2021 Oct 21;12:726448._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/21152103">10: Medendorp K, Vreede L, van Groningen JJ, Hetterschijt L, Brugmans L, Jansen PA, van den Hurk WH, de Bruijn DR, van Kessel AG. The mitotic arrest deficient protein MAD2B interacts with the clathrin light chain A during mitosis PLoS One. 2010 Nov 30;5(11):e15128. </a>_x000D_ _x000D_ <strong>Products Related to Human CLTA Protein can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>